Evidence map›Paper›PMID 38464732›Full record

ArticleFrontiers in pharmacology2024

Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania.

Adina Turcu-Stiolica, Ion Udristoiu, Mihaela-Simona Subtirelu, Victor Gheorman, Madalina Aldea, Elena Adriana Dumitrescu, Simona Ruxandra Volovat, Dragos Mircea Median, Cristian Virgil Lungulescu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adina Turcu-Stiolica *Pharmacoeconomics Department, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Ion UdristoiuPsychiatry Department, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Mihaela-Simona SubtireluPharmacoeconomics Department, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Victor Gheorman *Psychiatry Department, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Madalina Aldea *Psychiatry Department, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Elena Adriana DumitrescuDoctoral School, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Simona Ruxandra VolovatDepartment of Medical Oncology, University of Medicine and Pharmacy Grigore T. Popa Iasi, Iasi, Romania.
Dragos Mircea MedianGynecologic Oncology Department, Filantropia Clinical Hospital Bucharest, Bucharest, Romania.
Cristian Virgil LungulescuOncology Department, University of Medicine and Pharmacy of Craiova, Craiova, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

abemaciclibadherencebreast cancerCDK 4/6 inhibitorspalbociclibproportion of days covered (PDC)ribociclib

Identifiers

PMID38464732
PMCPMC10920324

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.